Abstract
Immunoglobulin therapy represents a lifesaving intervention for many patients with primary immunodeficiency (PID). Antibody defects represent approximately half of the well-known PIDs requiring immunoglobulin replacement therapy. Following immunoglobulin therapy in PID patients, protection against serious upper and lower respiratory tract infections and pulmonary function improves which leads to an increase in the quality of life of these patients. Successful treatment of PID patients depends on the type of immunodeficiency, regular monitoring of the patient, comorbidities of the patient, and the availability of the products.
Keywords: Immunoglobulin, infection, primary antibody deficiency, primary immunodeficiency diseases.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Volume: 16 Issue: 2
Author(s): Gholamreza Azizi, Hassan Abolhassani, Mohammad Hosein Asgardoon, Javad Rahnavard, Majid Zaki dizaji, Reza Yazdani, Javad Mohammadi and Asghar Aghamohammadi
Affiliation:
Keywords: Immunoglobulin, infection, primary antibody deficiency, primary immunodeficiency diseases.
Abstract: Immunoglobulin therapy represents a lifesaving intervention for many patients with primary immunodeficiency (PID). Antibody defects represent approximately half of the well-known PIDs requiring immunoglobulin replacement therapy. Following immunoglobulin therapy in PID patients, protection against serious upper and lower respiratory tract infections and pulmonary function improves which leads to an increase in the quality of life of these patients. Successful treatment of PID patients depends on the type of immunodeficiency, regular monitoring of the patient, comorbidities of the patient, and the availability of the products.
Export Options
About this article
Cite this article as:
Azizi Gholamreza, Abolhassani Hassan, Asgardoon Hosein Mohammad, Rahnavard Javad, dizaji Zaki Majid, Yazdani Reza, Mohammadi Javad and Aghamohammadi Asghar, The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases, Endocrine, Metabolic & Immune Disorders - Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1871530316666160724214418
DOI https://dx.doi.org/10.2174/1871530316666160724214418 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets Opioids and Cannabinoids Interactions: Involvement in Pain Management
Current Drug Targets From Cocaine to Ropivacaine: The History of Local Anesthetic Drugs
Current Topics in Medicinal Chemistry Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
Current Pharmaceutical Design Protein-Energy Malnutrition Alters Thermoregulatory Homeostasis and the Response to Brain Ischemia
Current Neurovascular Research Role of Microglia in the Pathogenesis of Sepsis-Associated Encephalopathy
CNS & Neurological Disorders - Drug Targets Recent Patents on Ophthalmic Nanoformulations and Therapeutic Implications
Recent Patents on Drug Delivery & Formulation Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology Environmental Toxicants as Extrinsic Epigenetic Factors for Parkinsonism: Studies Employing Transgenic C. elegans Model
CNS & Neurological Disorders - Drug Targets Adoptive Regulatory T-cell Therapy Attenuates Subarachnoid Hemor-rhage-induced Cerebral Inflammation by Suppressing TLR4/NF-B Signaling Pathway
Current Neurovascular Research Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Zolpidem Arousing Effect in Persistent Vegetative State Patients: Autonomic, EEG and Behavioral Assessment
Current Pharmaceutical Design Metabolic Acidosis in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Under-Dosing of Etomidate for Rapid Sequence Intubation in the Emergency Department
Current Drug Safety Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets
CNS & Neurological Disorders - Drug Targets A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews